Amedisys Reports First Quarter 2021 Financial Results Updates 2021 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Amedisys (AMED) Tops Q1 EPS by 7c
April 28, 2021 4:13 PM EDTAmedisys (NASDAQ: AMED) reported Q1 EPS of $1.50, $0.07 better than the analyst estimate of $1.43. Revenue for the quarter came in at $537.14 million versus the consensus estimate of $544.86 million.
Paul B. Kusserow, Chairman and Chief Executive Officer stated, I am proud of our first quarter results and our continued performance in our four... More
